MarketScreener Editorial Features Altimmune, Inc.
Equities
ALT
US02155H2004
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.230 USD | -0.24% |
|
+4.44% | +17.17% |
| 01-05 | Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH | CI |
| 01-05 | Altimmune Says US FDA Grants Breakthrough Therapy Designation for Pemvidutide in MASH | MT |
MarketScreener Editorial Features
Search
 | Central banks to the rescue | March 21, 2023 at 09:59 am |
 | Today on Wall Street: How yesterday’s data could affect Fed policy | June 16, 2021 at 08:37 am |
 | GLOBAL MARKETS LIVE: Alibaba faces heavy fine, good news for Boeing… | March 12, 2021 at 10:14 am |
No results for this search
- Stock Market
- Equities
- ALT Stock
- News Altimmune, Inc.
- MarketScreener Editorial Features
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition